Key result
Black/Other breast cancer patients face ~30% higher mortality than White/Asian patients, driven by those without comorbidities.
Why the study?
The role of comorbidities in shaping racial differences in breast cancer survival across cancer stages is unclear, with emerging data suggesting comorbidities may mask racial disparities.
Does race and comorbidity burden impact all-cause mortality in breast cancer patients?
Does race and comorbidity burden impact all-cause mortality in breast cancer patients?
Racial disparities in breast cancer survival are significant but may be masked by the presence of comorbidities, emerging primarily in patients without other medical illnesses.
No takes yet. Share an insight, caveat, or question.
Observed disparities without comorbidities merit prospective validation; leaves open targeted mitigation strategies.
Sanborn et al. (2026) studied this question. Black/Other breast cancer patients had 30% higher all-cause mortality (HR 1.3) than White/Asian patients, with racial disparities evident only in patients without comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: